Article (Scientific journals)
Management of immune checkpoint inhibitor in patients with cancer and pre-existing inflammatory bowel disease: Recommendations from the GETAID.
Amiot, Aurelien; Laharie, David; Malamut, Georgia et al.
2022In Digestive and Liver Disease, 54 (9), p. 1162-1167
 

Files


Full Text
Management of immune checkpoint inhibitor in patients with cancer...recommandations from the GETAID_Dig Liver Dis PPE.pdf
Publisher postprint (2.82 MB) Creative Commons License - Attribution
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Immune Checkpoint Inhibitors; Colitis; Diarrhea; Humans; Inflammatory Bowel Diseases; Neoplasms; Recurrence; Retrospective Studies; Crohn's disease; Immune checkpoint inhibitor; Inflammatory bowel disease; Ulcerative colitis
Abstract :
[en] BACKGROUND AND AIMS: There is no consensus on the management of immune checkpoint inhibitor (ICI) for treating cancer in patients with pre-existing inflammatory bowel disease (IBD). The Groupe d'Étude Thérapeutique des Affections Inflammatoires du tube Digestif (GETAID) aimed to provide recommendations on this topic. METHODS: A dedicated working group performed a comprehensive expert-based review of the literature, generated clinical key question and shaped recommendations that were further voted for approval by the educational and scientific committees of the GETAID. Using consensus methods, treatment modalities were defined by vote. RESULTS: Majority of patients with IBD in clinical remission can be treated with ICI after cancer diagnosis. The rate of relapse or immune-related diarrhoea or colitis upon ICI treatment is up to 39.8% and is maximal with ICI combination therapy compared to monotherapies. When starting ICI in a patient with IBD, it is recommended to assess disease activity and pursue ongoing maintenance therapy. In case of relapse or immune-related diarrhoea or colitis upon ICI treatment, treatment depends on grading of diarrhoea or colitis and may include corticosteroid therapy, infliximab and/or vedolizumab. CONCLUSIONS: In the present publication, we provided recommendations, which may assist gastroenterologists, haematologists, and oncologists for a better management of patients with pre-existing IBD before and during cancer treatment with ICI.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Amiot, Aurelien;  Department of Gastroenterology, Hopitaux Universitaires Bicêtre, AP-HP, Universite Paris Est Creteil, Le Kremlin Bicêtre, France, INSERM, Centre for Research in Epidemiology and Population Health, Institut Gustave Roussy, Université Paris Saclay, Villejuif, France. Electronic address: aurelien.amiot@aphp.fr.
Laharie, David;  CHU de Bordeaux, Hôpital Haut-Lévêque, Service d'Hépato-gastroentérologie et oncologie digestive - Université de Bordeaux, F-33000 Bordeaux, France.
Malamut, Georgia;  Department of Gastroenterology, AP-HP-Centre, Université de Paris, Hôpital Cochin, Paris, France.
Serrero, Melanie;  Department of Gastroenterology, University Hospital of Marseille Nord, Aix-Marseille, Marseille University, Marseille, France.
Poullenot, Florian;  CHU de Bordeaux, Hôpital Haut-Lévêque, Service d'Hépato-gastroentérologie et oncologie digestive - Université de Bordeaux, F-33000 Bordeaux, France.
educational committee of the, G E T A I D
Other collaborator :
Peyrin-Biroulet, Laurent
Laharie, David
Bourreille, Arnaud
Vuitton, Lucine
Bouguen, Guillaume
Abitbol, Vered
Amiot, Aurelien
Biron, Amelie
Bourrier, Anne
Caillo, Ludovic
Fumery, Mathurin
Gilletta, Cyrielle
Plastaras, Laurianne
Serrero, Melanie
Simon, Marion
Viennot, Stephanie
Seksik, Philippe
Attar, Alain
Buisson, Anthony
Caron, Benedicte
Charkaoui, Maeva
Gornet, Jean-Marc
Guillo, Lucas
Berre, Catherine Le
Louis, Edouard  ;  Centre Hospitalier Universitaire de Liège - CHU > > Service de gastroentérologie, hépatologie, onco. digestive
Malamut, Georgia
Mathieu, Nicolas
Nachury, Maria
Nancey, Stephane
Paul, Stephane
Reenaers, Catherine ;  Centre Hospitalier Universitaire de Liège - CHU > > Service de gastroentérologie, hépatologie, onco. digestive
Treton, Xavier
Uzzan, Mathieu
Wils, Pauline
More authors (24 more) Less
Language :
English
Title :
Management of immune checkpoint inhibitor in patients with cancer and pre-existing inflammatory bowel disease: Recommendations from the GETAID.
Publication date :
September 2022
Journal title :
Digestive and Liver Disease
eISSN :
1878-3562
Volume :
54
Issue :
9
Pages :
1162-1167
Commentary :
Copyright © 2022 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
Available on ORBi :
since 25 January 2024

Statistics


Number of views
36 (0 by ULiège)
Number of downloads
79 (0 by ULiège)

Scopus citations®
 
8
Scopus citations®
without self-citations
6
OpenCitations
 
5

Bibliography


Similar publications



Contact ORBi